Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 5

Results For "Bridge"

224 News Found

Wockhardt files marketing authorisation application for WCK 5222 with EMA
News | January 08, 2026

Wockhardt files marketing authorisation application for WCK 5222 with EMA

WCK 5222 is the first New Chemical Entity (NCE) discovered and developed in India to be submitted for pan-European marketing authorisation


UK to get groundbreaking early detection test for bowel cancer
R&D | December 22, 2025

UK to get groundbreaking early detection test for bowel cancer

Using a combination of blood and faecal samples, the service examines key biomarkers, including hereditary genetic status


Replacing confusion with clarity: Global Cancer Care launches Mumbai ops to tackle detection delays
News | December 21, 2025

Replacing confusion with clarity: Global Cancer Care launches Mumbai ops to tackle detection delays

The initiative is focused on a problem that continues to plague cancer outcomes in India


Merck KGaA launches ChemiSphere App to digitize lab workflows
Digitisation | December 17, 2025

Merck KGaA launches ChemiSphere App to digitize lab workflows

The ChemiSphere app exemplifies how M-Trust technology transforms workflows into seamless digital experiences


Formation Bio snaps up global rights to next-gen CNS TYK2 inhibitor from Lynk Pharma
News | December 12, 2025

Formation Bio snaps up global rights to next-gen CNS TYK2 inhibitor from Lynk Pharma

LNK01006 is designed to deliver potent, selective inhibition of TYK2-mediated cytokine signaling with central nervous system exposure


Dr. Lal PathLabs launches India's first complement testing lab
News | November 27, 2025

Dr. Lal PathLabs launches India's first complement testing lab

The Complement Laboratory is equipped with state-of-the-art immunoturbidimetric and ELISA platforms and adheres to CAP and NABL accreditation standards


FDA grants accelerated approval to sevabertinib for non-squamous non-small cell lung cancer
Drug Approval | November 21, 2025

FDA grants accelerated approval to sevabertinib for non-squamous non-small cell lung cancer

HER2-mutant NSCLC typically has a poor prognosis and limited treatment options